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Emerging hemodynamic signatures of the right heart
(Third International Right Heart Failure Summit, part 2)
Bradley A. Maron
Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School,
Boston, Massachusetts, USA; and Department of Cardiology, Veterans Affairs Boston Healthcare System, Boston, Massachu-
setts, USA
Abstract: Despite the importance of preserved right ventricular structure and function with respect to out-
come across the spectrum of lung, cardiac, and pulmonary vascular diseases, only recently have organized
efforts developed to consider the pulmonary vascular–right ventricular apparatus as a speciﬁc unit within the
larger context of cardiopulmonary pathophysiology. The Third International Right Heart Failure Summit
(Boston, MA) was a multidisciplinary event dedicated to promoting a dialogue about the scientiﬁc and
clinical basis of right heart disease. The current review provides a synopsis of key discussions presented
during the section of the summit titled “Emerging Hemodynamic Signatures of the Right Heart.” Speciﬁ-
cally, topics emphasized in this element of the symposium included (1) the effects of pulmonary vascular
dysfunction at rest or provoked by exercise on the right ventricular pressure-volume relationship, (2) the role
of pressure-volume loop analysis as a method to characterize right ventricular inefﬁciency and predict right
heart failure, and (3) the importance of a systems biology approach to identifying novel factors that contrib-
ute to pathophenotypes associated with pulmonary arterial hypertension and/or right ventricular dysfunc-
tion. Collectively, these concepts frame a forward-thinking paradigm shift in the approach to right heart
disease by emphasizing factors that regulate the transition from adaptive to maladaptive right ventricular–
pulmonary vascular (patho)physiology.
Keywords: right heart failure, nomenclature.
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In the autumn of 2013, the Third International Right
Heart Failure Summit convened in Boston, Massachu-
setts, to discuss contemporary concepts in the pathobiol-
ogy and clinical management of right-sided cardiovas-
cular disease. This symposium, which brought together
international experts across a range of scientiﬁc and clin-
ical ﬁelds, aimed to accomplish the following objectives:
deﬁne a standardized vocabulary by which to discuss
right heart disease,
1 present contemporary observations
relevant to right ventricular (RV)–pulmonary vascular
axis pathophysiology, and promote a dialogue about ap-
proaches to the care of patients with right heart failure
syndromes. To accomplish these objectives, the summit
was divided into three sections, titled (1) “Pulmonary
Hypertension and the Right Ventricle—Thinking out-
side the Box,” (2) “Emerging Hemodynamic Signatures
of the Right Heart,” and (3) “Transplantation in End-
Stage Pulmonary Hypertension.” The salient scientiﬁc
and clinical points of each section will be the feature of a
review article series in Pulmonary Circulation, with sec-
tion 2 being the focus of the current work.
EMERGING HEMODYNAMIC SIGNATURES
OF THE RIGHT HEART
The normal RV pressure-volume relationship
This section of the symposium addressed the RV–
pulmonary vascular relationship as a prism by which to
study and predict maladaptive and clinically meaningful
changes to right heart function.
2,3 This discussion was ini-
tiated by Dr. Andrew Redington, who reviewed the sig-
niﬁcance of RV pressure-volume assessment as a tool to
monitor the consequences of pulmonary vascular dysfunc-
tionwith respectto RVperformance.
The geometric and functional parameters of the nor-
mal left ventricle (LV) have been characterized thoroughly,
and the effect of perturbations to LV systolic and diastolic
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in patients has been described across virtually all forms of
left-sided cardiovascular disease, including ischemic
4 and
genetic
5 cardiomyopathies as well as pericardial disease.
6
By contrast, substantially fewer data on the RV pressure-
volume relationship under (patho)physiological conditions
are available.
7 This is due, in part, to the conformation of
the RV chamber, which does not align with a simple geo-
metric shape; thus, classical work using traditional non-
invasive imaging (e.g., two-dimensional echocardiography,
roentgenography) to calculate changes in RV cavitary vol-
ume across the cardiac cycle werelargelyconfounded.
8Even
inthecardiacmagneticresonance(CMR)imagingera,mon-
itoring with precision changes in RV volume or ejection
fraction under different loading conditions characterizes
global RV function in general, but most CMR indexes used
in clinical practice are static measures that do not offer
insight into the mechanistic underpinnings of RV con-
tractile efﬁciency and/or the factors modulating a transi-
tion from adaptive to maladaptive RV remodeling.
Increased afterload mediates changes to the
RV pressure-volume relationship
Seminal work in this ﬁeld by Dr. Redington and colleagues
characterized several key features unique to the normal
RV pressure-volume relationship in humans (Fig. 1).
10
First, the pressure-volume loop is triangular in conforma-
tion. Second, blood ejection occurs early in the RV pres-
sure upstroke, with ∼4% of stroke volume being ejected
prior to peak RV systolic pressure. Third, a majority of
stroke volume is ejected after peak RV systolic pressure;
thus, the isovolumic relaxation phase is substantially less
well deﬁned in the RV than the LV. These investigators
would later characterize the effects of changes to loading
conditions on the RV pressure-volume relationship in hu-
mans. Whereas increased volume loading does not change
the loop shape or ejection pattern signiﬁcantly, increased
RV afterload (e.g., subpulmonic valvular stenosis, increased
pulmonary vascular resistance [PVR]) results in a blunted
rate of ejection during RV pressure decline and a distinct
isovolumic relaxation phase.
9,11
These observations describe the fundamental character-
istics that distinguish the RV pressure-volume relationship
from the LV pressure-volume relationship under condi-
tions of altered volume and pressure loading and establish
a model by which to study RV efﬁciency with respect to
pulmonary vascular function (i.e., RV–pulmonary arterial
coupling).
3,12 In fact, subsequent empiric efforts have es-
tablished that predicting pathological changes to the RV
pressure-volume loop contour hinges on the severity and
time course of increases in RV afterload. In one study of
experimental pulmonary embolism
13 in which swine were
subjected to autologous pulmonary artery blot clot, RV con-
ductance catheterization was performed to assess changes
in pulmonary arterial elastance (Ea;i . e . ,R Va f t e r l o a d ) ,R V
end-systolic elastance (EES; i.e., load-independent contrac-
tility), and the EES∶Ea ratio, which is an assessment of RV–
pulmonary arterial coupling (Fig. 2). In that study, a sig-
niﬁcant increase in Ea and EES was observed beginning
30 minutes after embolization, with a maximum peak
within 4 hours. These changes resulted in an initial de-
creasein theEES∶Ea ratioand an attendantoptimization of
RV stroke volume. However, as predicted by Redington and
colleagues,
9-11 late responses to gradually increased RV
afterload ultimately resulted in decreased RV stroke vol-
ume and maladaptive RV cavitary dilation.
These trends have been reproduced in studies of chronic
right heart failure. In animals subjected to pulmonary ar-
terial banding or treatment with monocrotaline to induce
acuteandchronicpulmonaryhypertension,respectively,in-
creased EES and preload recruitable RV stroke work were
observed.
15 However, changes in these pressure-volume
indexes are more pronounced in acute rather than chronic
pulmonary hypertension and appear to be contingent
largely on RV diastolic function rather than RV free-wall
thickness. Along these lines, the importance of RV dia-
Figure 1. Normal human right ventricular (RV) pressure-volume
loop. In seminal work by Redington and colleagues to character-
ize the normal RV pressure-volume loop, Simpson’s rule was
used to calculate the RV chamber volume from biplane ven-
triculograms that were derived from radiopaque casts of the hu-
man RV (A). Simultaneous pressure measurements were re-
corded using a micromanometer catheter placed in the apex of
the RV (B), and the complete pressure-volume loop contour was
created by superimposing volume and pressure measurements
(C). Reproduced with permission from Redington et al.
9
706 | Right heart hemodynamic signatures Maronstolic function to the pathophysiology of PAH in patients
has been reported recently. For example, Rain et al.
16 per-
formed single-beat RV pressure-volume analyses in 7 con-
trols and 21 patients with PAH due largely to connective
tissue and congenital heart disease. Their ﬁndings sug-
gest that RV diastolic stiffness was increased signiﬁcantly
in PAH, possibly through a mechanism involving the pro-
tein titin in RV cardiomyocytes, which regulates sarcomeric
stiffness.
Left heart disease and the RV pressure-volume
relationship
The effect of increased left heart afterload on RV perfor-
mance has generated provocative insight into the mecha-
nism(s) that determine RV cardiac output. In one study of
experimental chronic RV pressure overload in rabbits, aor-
tic constriction decreased RV cavitary dimension and im-
proved RV contractile performance.
17 Compared with the
RV failure condition alone, aortic banding also attenuated
histopathological evidence of adverse RV cardiomyocyte
remodeling and decreased RV messenger RNA (mRNA)
expression levels of matrix metalloproteinase 9 and trans-
forming growth factor β, which are key signaling interme-
diaries involved in extracellular matrix metabolism and
collagen deposition, respectively.
18 Overall, ﬁndings from
this and other similar studies
19 illustrates the importance
of interventricular dependence on RV geometry and per-
formance and suggests that increased LV afterload pro-
motes recruitment of the interventricular septum by the
RV to maintain (or augment) RV stroke volume. The im-
plications of these collective observations to patients con-
tinue to be explored, although technical factors associated
with accurately measuring the RV pressure-volume rela-
tionship are an important consideration to the use of
these methods in routine clinical practice.
20
HEMODYNAMIC PITFALLS AND PEARLS
In this segment of the symposium, Drs. Michael Landz-
berg and Alexander Opotowsky used a case-based approach
to discuss strategies to synthesize a differential diagnosis
and therapeutic approach to patients with various forms
of right heart disease, particularly congenital heart
21 and
exercise-induced pulmonary vascular
22 diseases. The speak-
ers noted that a dilemma common to the management of
this patient population is clinical decision making in
asymptomatic or minimally symptomatic patients despite
clinical evidence of active right heart disease. Additionally,
despite the acuity and severity of many pulmonary vascular
diseases, such as pulmonary arterial hypertension (PAH),
clinicians must remain alert to alternative causes to pa-
tients’ clinical presentations, such as competing cardio-
pulmonary diseases or other processes. To illustrate this
latter point, a clinical vignette was presented in which strat-
egies to characterize the contribution of aortic valve disease
to exercise intolerance in a patient with bona ﬁde PAH
were reviewed.
Aortic valve disease in patients with pulmonary
hypertension: cause or consequence?
The positive association between aortic valvular stenosis
(AS) and pulmonary vascular dysfunction was originally
reported more than 7 decades ago.
23 In one early study,
the cardiopulmonary hemodynamic proﬁle was evaluated
in a cohort of 74 veterans with surgical AS, which dem-
onstrated that at least moderate pulmonary hypertension
was present in 54% of patients and that aortic valve area
correlated inversely with pulmonary arterial pressure
(PAP).
24 These ﬁndings are in agreement with subsequent
observations reported in larger patient cohorts, including
one study of 388 symptomatic AS patients undergoing right
heart catheterization in which 63% had evidence of at least
moderate pulmonary hypertension.
25
The prognostic relevance of pulmonary hypertension
with respect to outcome in patients with AS is identiﬁed
as an important factor determining eligibility for mechan-
ical aortic valve replacement. In one recent prospective
Figure 2. The pressure-volume diagram is used to calculate right
ventricular (RV)–pulmonary vascular coupling. The pressure-
volume diagram allows for the determination of RV end-systolic
elastance (EES). EES is unaffected by changes to RV afterload (dashed
line) and, therefore, is the best possible load-independent measure-
ment of contractility. By contrast, arterial elastance (Ea) is propor-
tional to pulmonary vascular resistance and is a measurement of
RV afterload. The ratio of EES to Ea is a measure of the coupling of
the respective ventricular and arterial loads. Thus, a decrease in
EES (light gray arrow) or an increase in Ea (dark gray arrow) due
to elevations in pulmonary vascular resistance, for example, dis-
rupts normal coupling. Adapted with permission from Brimioulle
et al.
14
Pulmonary Circulation Volume 4 Number 4 December 2014 | 707trial involving 1,116 patients with surgical AS, severe pul-
monary hypertension was associated with increased age,
more severe multivessel coronary disease, lower LV ejec-
tion fraction, and increased probability of recent myocar-
dial infarction.
26 Furthermore, pulmonary hypertension
of any degree was an independent predictor of mortality
in the immediate postoperative period and over 5 years
of follow-up. Indeed, pulmonary vascular disease severity
has been raised as a potential clinical metric by which to
predict clinical response to aortic valve treatment. Severe
pulmonary hypertension (deﬁned by the investigators as
pulmonary arterial systolic pressure [PASP] of >60 mmHg)
predicted increased mortality at 8 months after transcath-
eter aortic valve implantation (TAVI; hazard ratio [HR],
1.88 [95% conﬁdence interval, 1.17–30]) in a prospective
analysis of 345 aortic valve procedures, which was akin to
other traditional high-risk clinical conditions, such as peri-
procedural sepsis.
27
Ben-Dor et al.
28 studied 509 patients with severe AS
evaluated for TAVI or balloon aortic valvuloplasty and ob-
served that higher preprocedural PAP was associated with
increased cardiovascular symptom burden, more severe re-
nal insufﬁciency, and higher left ventricular end-diastolic
pressure. In that study, pulmonary hypertension severity
was abrogated immediately following TAVI (or surgical
AV replacement), and this change was generally sustained
1 year after the procedure, although data from our institu-
tion (unpublished) and others
29 suggest a less consistent
therapeutic beneﬁt to the pulmonary vasculature follow-
ing TAVI for aortic valve replacement.
Less well deﬁned is the role of pulmonary vasoreactivity
as a treatment target to improve outcome in patients with
aortic valve disease. Among 20 patients with severe AS and
pulmonary hypertension (mean PASP, 55 mmHg; PVR,
3.5 Wood units), the oral phosphodiesterase type 5 in-
hibitor sildenaﬁl (40 or 80 mg) was well tolerated when
administered as single dose and induced an immediate
improvement in PASP, PVR, and LV stroke volume index
by −25% (P < 0.001), −29% (P < 0.001), and +8% (P = 0.05),
respectively.
30 Despite these encouraging data, larger stud-
ies are required to characterize further the potential bene-
ﬁts of pulmonary vasodilator therapy in patients treated
medically for aortic stenosis or undergoing valve replace-
ment. It is also worthwhile to note that patient fragility
and low distance achieved in the 6-minute walk test
31 are
established factors that predict outcome in patients under-
going TAVI or surgical aortic valve replacement, although
the contribution of pulmonary vascular disease at rest or
provoked by exertion to this effect is not known.
EXERCISE-INDUCED PULMONARY
HYPERTENSION: WHEN DOES PHYSIOLOGY
TRANSITION TO PATHOLOGY?
The factors that promote abnormal RV and pulmonary
vascular response patterns to exercise are incompletely
characterized, despite the critical importance of physical
activity to the development of right heart failure symp-
toms provoked by exertion. In fact, although numerous
reports have established metrics that deﬁne abnormal
functional capacity and cardiovascular ﬁtness occurring
in concert with irregular exertional cardiopulmonary he-
modynamics, a standardized hemodynamic deﬁnition for
exercise-induced pulmonary hypertension remains lack-
ing.
32 Traditional models have largely emphasized pul-
monary vascular dysfunction due to abnormal blood
vessel compliance, reactivity, and stiffness as critical deter-
minants of developing exercise-induced PAH (EI-PAH).
33
However, changes to RV cavitary dimension and systolic
function due to RV–pulmonary vascular uncoupling is in-
creasingly recognized as a mediator of the EI-PAH patho-
phenotype
34 and was explored further in this section of the
summit.
The pivotal role of RV function in determining
cardiopulmonary responses to exercise
Observations from elite athletes identiﬁes two forms of
RV remodeling based on endurance (e.g., swimming, long-
distance running) versus isometric (e.g., weight lifting)
activities, which results in eccentric biventricular remodel-
ing (including RV dilation) and concentric LV remodel-
ing in the absence of signiﬁcant changes to RV structure/
function, respectively (Fig. 3).
35 The mechanism(s) under-
pinning these differences are unresolved; however, it has
been hypothesized that the mitral and aortic valves func-
tion as resistors to protect the pulmonary vascular–RV cir-
cuit from afterload bursts generated by isometric activi-
ties. By contrast, RV involvement in the (patho)phenotype
of endurance athletes is ascribed, in part, to the effects
of subchronic elevations in cardiac output associated with
repetitive aerobic activity on pulmonary vascular function
that increases RV cavitary dimension and PAP.
36
Recent reports suggest further that RV cardiomyocyte
recovery kinetics may modulate, in part, the right heart
response to exercise.
37,38 La Gerche et al.
37 used CMR im-
aging to characterize the effects of ultraendurance ath-
letic activity on RV performance. Their observations sug-
gest that, compared with the preparticipation state, RV
function is signiﬁcantly impaired in the time period imme-
diately following extremely long endurance events, such as
708 | Right heart hemodynamic signatures Maronmarathon running (3 hours in duration) and ultratriath-
lons (11 hours in duration). Interestingly, they also identi-
ﬁed a correlation between event duration and severity of
RV functional impairment but noted that RV recovery was
observed in most athletes by 12 days after the competition
(Fig. 4). Presumably, these reversible changes to RV struc-
ture and function in elite athletes describe adaptive or only
minimally maladaptive changes to cardiovascular func-
tion provoked by physical activity. Taken together, these
observations illustrate the importance of characterizing
further factors that promote divergence from normal RV
exercise-response patterns.
Deﬁning determinants of RV work: hydraulic power
and RV–pulmonary vascular coupling
Even subtle perturbations to RV loading conditions are
associated with unfavorable changes to right heart func-
tion.
39 Yet increased RV afterload is tolerated to vary-
ing degrees across the spectrum of cardiopulmonary
disease,
40,41 while assessing RV systolic function, such as
ejection fraction, is not synonymous with measuring RV
efﬁciency. To accomplish this, it may be useful to quan-
tify the mechanical pump properties of the RV chamber
inthe context of pulmonary circulatory function.
42
One method to accomplish this is by deﬁning RV hy-
draulic power as the energy per unit of time required to
produce a steady ﬂow of blood through the pulmonary
circuit. This is quantitated by the product of cardiac out-
put and mean PAP (mPAP).
43,44 Within this construct,
ﬂow through the pulmonary vascular circuit will require
a mean and oscillatory fraction of hydraulic power, which,
in turn, exerts differing functionalities to the RV–pulmonary
vascular relationship. On the one hand, the mean oscil-
latory fraction describes the contribution of RV hydraulic
power to the biologically relevant component(s) of the sys-
tem: blood ﬂow and, thus, oxygen transport. On the other
hand, the oscillatory fraction of hydraulic power describes
the contribution of RV hydraulic power to the mechanical
arm of the system, which is pulmonary arterial pulsatility
and blood pressure. Under experimental conditions, the RV
oscillatory fraction is ∼23%, which is substantially higher
than that reported for the LV (10%).
43
It reasons that factors that alter normal RV loading
conditions—such as the pulmonary vascular ﬁbrosis, in-
ﬂammation, and blood vessel thickening that occur in
PAH, for example—will potentiate a shift in the RV hy-
draulic power dynamic in favor of an increased oscillatory
fraction.
45 To illustrate this further, consider Figure 5,
which illustrates pulmonary vascular distensibility as a
nonlinear relationship between cardiac output and mPAP.
Under experimental conditions, cardiac output associates
positively with pulmonary vascular distensibility up to
∼30 L/min. In healthy individuals, the distensibility co-
efﬁcient is ∼2%, which protects the RV somewhat against
an increase in afterload during activity.
46 The extent to
which intrinsic disease of the pulmonary vasculature
alters the slope of this curve, however, has not yet been
fully characterized. Nevertheless, it is clear that, at least
in the diseased state, pulmonary arterial compliance cor-
relates inversely with RV function, as suggested by nu-
merous clinical reports in patients with various forms
of pulmonary hypertension.
47,48 From these collective ob-
servations, the interrelatedness of pulmonary circulatory
and RV function comes into focus.
Assessing RV efﬁciency through the pressure-volume
loop model
The extent to which a disruption in the balance between
the mean and oscillatory fractions of hydraulic work inﬂu-
ences normal RV performance may be expressed vis-a `-vis
Figure 3. Differential effect on right heart adaptation of endur-
ance or isometric exercise. Exercise-induced remodeling patterns
tend to be associated with athletic activity type, which is due to
activity-speciﬁc changes in cardiopulmonary physiology. For ex-
ample, isometric exercises (e.g., competitive weight lifting), char-
acterized by sudden bursts of increased afterload, increase left
ventricular (LV) pressure-loading conditions and promote LV
hypertrophy. By contrast, the right ventricle (RV) is generally
spared from remodeling in isometric exercise, an effect hypoth-
esized to occur as a consequence of left heart valve–mediated
protection of the pulmonary circulation and RV from increased
systemic pressure. In endurance exercise, sustained increases
in cardiac output alters volume-loading conditions to both the
LV and the RV, resulting in RV dilation and, to a lesser degree, hy-
pertrophy that occurs in addition to left heart remodeling.
Pulmonary Circulation Volume 4 Number 4 December 2014 | 709Figure 4. Changes to right ventricular geometry and performance as a function of time following extreme athletic participation. La
Gerche et al.
37 recently reported changes to right ventricular (RV) structure and function in a group of marathon runners, alpine
cyclers, endurance triathletes, and ultratriathletes, assessed by echocardiography (ECHO) or cardiac magnetic resonance imaging
(MRI) within 2 weeks of competition (baseline), immediately after the completion of competition (postrace), and within 6–11 days
after the competition (delayed). Overall, these data raise speculation that differences in RV cardiomyocyte recovery kinetics may
inﬂuence the right heart response patterns to exercise. EF: ejection fraction; TAPSE: tricuspid annular plane systolic excursion. Adapted
with permission from La Gerche et al.
37
changes to the pressure-volume relationship (Fig. 2). As
discussed by Dr. Redington (see the section “The normal
RV pressure-volume relationship” above), the RV end-
systolic elastance (EES) is a load-independent measure of
myocardial contractility and is deﬁned as the maximal
pressure generated by the RV at a particular volume. Arte-
rial elastance (Ea), which is calculated by the ratio of RV
end-systolic pressure to stroke volume, is proportional to
PVR and, thus, operates as a measurement of RV after-
load.
49 Taken together, the ratio of EES to Ea is a measure
of the coupling of ventricular contractility and pulmonary
arterial load. Thus, a decrease in EES (i.e., contractility) or
an increase in Ea (i.e., due to elevated PVR) disrupts nor-
mal coupling.
To investigate the physiological relevance of these rela-
tionships, Brimioulle et al.
14 performed a series of clever ex-
periments in dogs to assess the RV end-systolic pressure-
volume relationship in response to various stimuli designed
to mimic exercise. In that study, pharmacological activation
of β-adrenergic signaling with dobutamine increased the
EES∶Ea ratio, primarily through effects on RV contractility
rather than PVR. Thus, under conditions of enhanced RV
contractility, improvements to cardiac output may occur at
the expense of RV hydraulic efﬁciency, although proving
this in the exercising human requires further investigation.
While interrogating the consequences of exercise with
respect to RV–pulmonary vascular coupling by pressure-
volume analysis remains a difﬁcult task practically, Tolle
et al.
50 demonstrated that among a cohort of patients un-
dergoing invasive exercise hemodynamic monitoring,
three subphenotypes merged: normal, in whom the car-
diopulmonary hemodynamics were normal at rest and
a >50% decrease in PVR was observed at peak exercise;
patients meeting hemodynamic criteria for PAH at rest,
in whom PVR declined slightly or was increased with
exercise; and EI-PAH patients, in whom hemodynamics
were normal at rest but functional capacity was dimin-
ished and PVR decline at rest was below anticipated lev-
els. These dynamic cardiopulmonary hemodynamic changes
were not contingent on changes in LV end-diastolic pres-
710 | Right heart hemodynamic signatures Maronsure, indicating intrinsic disease of the pulmonary vascu-
lature. In that study, the downstream consequences of
increased PVR on RV–pulmonary arterial coupling was
examined indirectly by measuring the relationship be-
tween mPAP and maximal volume of oxygen consumption
(V
:
o2). In the “takeoff pattern,” which is generally associ-
ated with normal or near-normal exercise function, a limi-
tation of V
:
o2 by mPAP was observed, although this effect
was late after exercise initiation and, thus, is believed to
reﬂect maximal pulmonary vascular distensibility achieved
by increased cardiac output during exercise (Fig. 6A). By
contrast, an early increase in the mPAP-V
:
o2 relationship
was observed in patients with EI-PAH and resting PAH
and is hypothesized to represent signiﬁcant RV dysfunc-
tion due to RV-arterial uncoupling (Fig. 6B).
THE SYSTEMS PATHOBIOLOGY OF PAH:
A NETWORK MEDICINE APPROACH
Dr. Joseph Loscalzo discussed an evolving paradigm shift
in the methods by which human diseases, including pul-
monary vascular disease, are studied, analyzed, and cate-
gorized. The traditional method for classifying human
disease is an organ-based approach that segregates pheno-
types largely along pathophysiological lines.
51 This time-
honored strategy is derived from the classical era of medi-
cine, in which microscopy or physical diagnosis alone was
sufﬁcient to diagnose diseases for the primary purpose of
prognosis.
52 However, in the genomic and molecular era
of science, the possibility of developing target-speciﬁc ther-
apies, such as monoclonal antibodies or small-molecule
inhibitors, is increasingly realized; thus, methods to con-
Figure 5. Pulmonary vascular distensibility curve. Modeled mean
pulmonary arterial pressure-ﬂow relationships at progressively
increased pulmonary vascular distensibility is expressed as per-
cent increase in diameter per millimeter of mercury of pressure.
Reproduced with permission from Naeije et al.
46
Figure 6. The relationship between mean pulmonary arterial
pressure (mPAP) and peak volume of oxygen consumption
(V
:
o2) during exercise is inﬂuenced by different forms of pul-
monary vascular disease. Two pathophysiological patterns un-
derpinning the pulmonary vascular limit to exercise are
identiﬁed by assessing the relationships between mPAP and
peak V
:
o2. A, In the “takeoff pattern,” which is generally associ-
ated with normal or near-normal exercise function, a limitation
of V
:
o2 by mPAP occurs, but it is a late effect after exercise
initiation. This pattern is believed to reﬂect the effects of lim-
ited pulmonary vascular distensibility. B, By contrast, an early
increase in the mPAP-V
:
o2 relationship is observed in patients
with exercise-induced pulmonary arterial hypertension (PAH)
and PAH at rest, which may represent signiﬁcant right ventric-
ular (RV) dysfunction due to RV-arterial uncoupling. Adapted with
permission from Tolle et al.
50
Pulmonary Circulation Volume 4 Number 4 December 2014 | 711ceptualize diseases that consider a more precise patho-
phenotype classiﬁcation are desirable. This has particular
relevance to the ﬁeld of pulmonary vascular disease, in
which a swath of candidate molecules are implicated in
the development of PAH, deﬁned (somewhat vaguely) as
a unifying end phenotype according to general cardiopul-
monary hemodynamic criteria. In turn, delineating with
greater precision the basic factors that deﬁne PAH clini-
cal expression is anticipated to provide enhanced clarity
over current methods for matching affected patients to
disease-speciﬁc therapies.
53
There is substantial genetic overlap between selected,
common human disease pathophenotypes,
54 which has
been demonstrated using genome-wide association stud-
ies (GWASs)
55 and systems biology network methods.
56
The GWASs, which are performed using vast numbers
of patients sharing a common disease, have identiﬁed
genetic variability (i.e., single-nucleotide polymorphisms)
in association with disease prevalence. The GWAS strat-
egy, therefore, leverages large-scale epidemiological and
genetic methods to provide, as Dr. Loscalzo stated, a “lin-
ear narrative of disease” through the identiﬁcation of chro-
mosomal loci implicated in incident disease occurrence.
By contrast, a systems biology approach to deﬁning dis-
ease pathophenotype is multidimensional: a network of
molecular interactions (protein-protein, mRNA-mRNA,
etc.) regulating the development of an intermediate patho-
phenotype is generated mathematically, on the basis of the
curated literature or biological data sets, to identify novel
targets involved in disease expression (reviewed recently
by Silverman and Loscalzo
57).
The interactome and human disease
An overarching objective of network theory when applied
to biology is to depict quantitatively the interactions be-
tween proteins (or other key cellular components), clinical
phenotypes, and other variables relevant to understanding
disease pathophenotypes. This is based on the principle
that the functional effects of any single protein, for exam-
ple, involve targets residing in both the intracellular and
the extracellular compartment as well as at remote tissue/
organ sites.
58 Thus, the effect of a speciﬁc genetic abnor-
mality is likely to involve a range of other functionally rele-
vant interactions, which forms the links between targets
and, ultimately, the interactome. In fact, several published
data sets support the assertion that biological networks are
not randomand generate a pattern of clustering nodes.
58,59
The organization of node clusters may be grouped further
into protein modules, which represent highly linked vari-
ables. Overall, this framework unveils connectivity between
biologically relevant factors and/or clinical phenotypes.
In light of the observation that of 25,000 genes only
∼1,700 are implicated in human disease,
60 the impor-
tance of functional connectivity between genes and gene
Figure 7. Distribution of genes in the human interactome.
A, Depiction of the distribution of in utero essential versus
known disease genes identiﬁed among the ∼25,000 human
genes. B, Schematic diagram of the differences between essen-
tial and nonessential disease genes. Nonessential disease genes
(shown as blue nodes) are found to segregate at the network pe-
riphery, whereas in utero essential genes (shown as red nodes)
tend to be at the functional center (encoding hubs and expressed
in many tissues) of the interactome. A is reproduced with per-
mission from Goh et al.
61 B is reproduced with permission from
Baraba ´si et al.
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712 | Right heart hemodynamic signatures Maronproducts is more clearly realized. This may be depicted
schematically by the centralization of fetally lethal genes
and the distribution of nonessential genes to the periph-
ery of the human interactome (Fig. 7). Building on this
concept, disease modules are developed to express impor-
tant biological factors according to interactivity, function-
ality, or relevance, as deﬁned by association with a speciﬁc
disease in the presence of an expression-altering effector
(environmental factors, de novo mutation, etc.).
62,63 Col-
lectively, the network construct is a truly “ground-up” ap-
proach to classifying disease: key molecular interactions
associating with disease pathophenotype are identiﬁed,
which, in turn, link basic substrate abnormality to clinical
pathophenotype.
Systems biology and PAH
PAH is a heterogeneous disease in many respects, includ-
ing the involvement of numerous molecular mechanisms
identiﬁed in the development of pulmonary arterial thick-
ening, ﬁbrosis, and dysregulated pulmonary endothelial
and smooth muscle cell apoptosis. In this regard, PAH is
an excellent disease model for network biology analysis,
which is, in part, the subject of an ongoing National In-
stitutes of Health–sponsored consortium investigation
(MAPGen; http://www.mapgenprogram.org). Parikh et al.
64
constructed a PAH network consisting of 131 nodes and
26 functional pathways that, when subjected to mathe-
matical modeling, resulted in the development of a con-
solidated PAH interactome consisting of 115 nodes and
255 edges (i.e., interactions between nodes; Fig. 8). A sub-
set of microRNAs (miRNAs), which are noncanonical and
highly conserved noncoding ribonucleic acids,
65 were iden-
tiﬁed on the basis of their previously established role in
mediating cellular responses to hypoxia, inﬂammation, and
tissue growth factor β signaling. Of this group, miRNA-21
was studied further owing to its association with cellular
phenotypes implicated in PAH and the regulatory inﬂu-
ence observed by this particular miRNA on the network.
Findings in cultured pulmonary arterial endothelial cells
and in experimental PAH in vivo validated miRNA-21 in-
Figure 8. A proposed pulmonary hypertension (PH) network. The known ﬁrst-degree interactions (indicated by gray lines) are
displayed among the genes in the PH module. There exist a total of 115 nodes and 255 edges (interconnections). Reproduced with
some modiﬁcation with permission from Parikh et al.
64
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bone morphogenetic protein receptor type 2 and Rho ki-
nase signaling pathways. Taken together, these ﬁndings
demonstrate the potential for network biology to identify
novelmolecular links involved in the pathobiology of PAH.
CONCLUSIONS
A wide-ranging gamut of topics relevant to understanding
RV–pulmonary vascular (patho)physiology in the current
era was discussed in this section of the Third International
Right Heart Failure Summit. Classical studies analyzing
the RV pressure-volume relationship were reviewed and
evaluated in the context of contemporary data, particularly
regarding the effects of increased RV afterload and exer-
cise on RV work efﬁciency. Novel reports characterizing
changes to RV structure and function following competi-
tive athletic participation has generated important insight
into the potential contribution of RV myocyte recovery ki-
netics to determining adaptive versus maladaptive RV ex-
ercise response patterns in humans. Future work is likely
to continue to leverage a systems biology approach to un-
derstanding further the molecular underpinnings that reg-
ulate RV and pulmonary vascular function and modulate
the development of right heart pathophenotypes, particu-
larly PAH and RV failure.
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